PAULA STULTZ: Open Payments
NPI 1164569737 · BROWNWOOD, TX. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,125 in 63 payments from 17 companies in 2025. Trend: 2023 $533 · 2024 $1,218 · 2025 $1,125
Food & beverage: $1,035Education: $90
| Company | Payments | Amount |
|---|---|---|
| Janssen Biotech, Inc. | 12 | $249 |
| ABBVIE INC. | 13 | $199 |
| Takeda Pharmaceuticals U.S.A., Inc. | 10 | $159 |
| Celltrion USA Inc. | 5 | $90 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | 4 | $81 |
| Ipsen Biopharmaceuticals, Inc | 2 | $51 |
| Phathom Pharmaceuticals, Inc. | 3 | $44 |
| Ardelyx, Inc. | 2 | $38 |
| Madrigal Pharmaceuticals | 2 | $37 |
| Regeneron Healthcare Solutions, Inc. | 2 | $36 |
Products named: TREMFYA, ENTYVIO, VEGZELMA, XIFAXAN, RINVOQ, EOHILIA, SKYRIZI, IQIRVO.
Industry payments across TX — which companies pay providers there.
